206 related articles for article (PubMed ID: 19402372)
1. Role of chemotherapy in gastro-entero-pancreatic neuroendocrine tumors: the end of a story?
Delaunoit T; Van den Eynde M; Borbath I; Demetter P; Demolin G; Pattyn P; Pauwels S; Peeters M; Roeyen G; Van Cutsem E; Van Hootegem P; Van Laethem JL; Verslype C; Hendlisz A
Acta Gastroenterol Belg; 2009; 72(1):49-53. PubMed ID: 19402372
[TBL] [Abstract][Full Text] [Related]
2. Selecting patients for cytotoxic therapies in gastroenteropancreatic neuroendocrine tumours.
Costa FP; Gumz B; Pasche B
Best Pract Res Clin Gastroenterol; 2012 Dec; 26(6):843-54. PubMed ID: 23582923
[TBL] [Abstract][Full Text] [Related]
3. Irinotecan plus cisplatin followed by octreotide long-acting release maintenance treatment in advanced gastroenteropancreatic neuroendocrine carcinoma: IPO-NEC study.
Li J; Lu M; Lu Z; Li Z; Liu Y; Yang L; Li J; Zhang X; Zhou J; Wang X; Gong J; Gao J; Li Y; Shen L
Oncotarget; 2017 Apr; 8(15):25669-25678. PubMed ID: 27788498
[TBL] [Abstract][Full Text] [Related]
4. Refining the management of patients with gastroenteropancreatic neuroendocrine tumors.
Iyer R
Clin Adv Hematol Oncol; 2017 Apr; 15 Suppl 4(4):3-10. PubMed ID: 28654023
[No Abstract] [Full Text] [Related]
5. The antiproliferative effect of somatostatin analogs: clinical relevance in patients with neuroendocrine gastro-entero-pancreatic tumours.
Verslype C; Carton S; Borbath I; Delaunoit T; Demetter P; Demolin G; Hendlisz A; Pattyn P; Pauwels S; Peeters M; Roeyen G; Van Hootegem P; Van Laethem JL; Van Cutsem E
Acta Gastroenterol Belg; 2009; 72(1):54-8. PubMed ID: 19402373
[TBL] [Abstract][Full Text] [Related]
6. Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications.
Fazio N; Milione M
Cancer Treat Rev; 2016 Nov; 50():61-67. PubMed ID: 27636009
[TBL] [Abstract][Full Text] [Related]
7. Systemic treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETS): current approaches and future options.
Strosberg JR
Endocr Pract; 2014 Feb; 20(2):167-75. PubMed ID: 24014009
[TBL] [Abstract][Full Text] [Related]
8. Hematological toxicity of combined 177Lu-octreotate radiopeptide chemotherapy of gastroenteropancreatic neuroendocrine tumors in long-term follow-up.
Kesavan M; Claringbold PG; Turner JH
Neuroendocrinology; 2014; 99(2):108-17. PubMed ID: 24714208
[TBL] [Abstract][Full Text] [Related]
9. The potential role of targeted therapies in the management of neuroendocrine tumours.
Verset G; Borbath I; Delaunoit T; Demetter P; Demolin G; Hendlisz A; Pattyn P; Pauwels S; Peeters M; Roeyen G; Van Cutsem E; Van Hootegem P; Verslype C; Van Laethem JL
Acta Gastroenterol Belg; 2009; 72(1):59-62. PubMed ID: 19402374
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab-based combination therapy for advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a systematic review of the literature.
Abdel-Rahman O; Fouad M
J Cancer Res Clin Oncol; 2015 Feb; 141(2):295-305. PubMed ID: 24990591
[TBL] [Abstract][Full Text] [Related]
11. [Pharmacologic therapy for neuroendocrine tumours].
Petrányi A; Bodoky G
Orv Hetil; 2011 Mar; 152(10):379-91. PubMed ID: 21354954
[TBL] [Abstract][Full Text] [Related]
12. Somatostatin analog octreotide LAR in gastro-entero-pancreatic tumors.
Oberg K
Expert Rev Anticancer Ther; 2009 May; 9(5):557-66. PubMed ID: 19445573
[TBL] [Abstract][Full Text] [Related]
13. Neuroendocrine tumors: treatment updates.
Khagi S; Saif MW
JOP; 2013 Jul; 14(4):367-71. PubMed ID: 23846929
[TBL] [Abstract][Full Text] [Related]
14. Are G3 ENETS neuroendocrine neoplasms heterogeneous?
Vélayoudom-Céphise FL; Duvillard P; Foucan L; Hadoux J; Chougnet CN; Leboulleux S; Malka D; Guigay J; Goere D; Debaere T; Caramella C; Schlumberger M; Planchard D; Elias D; Ducreux M; Scoazec JY; Baudin E
Endocr Relat Cancer; 2013 Oct; 20(5):649-57. PubMed ID: 23845449
[TBL] [Abstract][Full Text] [Related]
15. New pharmacologic therapies for gastroenteropancreatic neuroendocrine tumors.
Lawrence B; Gustafsson BI; Kidd M; Modlin I
Gastroenterol Clin North Am; 2010 Sep; 39(3):615-28. PubMed ID: 20951920
[TBL] [Abstract][Full Text] [Related]
16. Association between somatostatin analogues and diabetes mellitus in gastroenteropancreatic neuroendocrine tumor patients: A Surveillance, Epidemiology, and End Results-Medicare analysis of 5235 patients.
Ni K; Yang JY; Baeg K; Leiter AC; Mhango G; Gallagher EJ; Wisnivesky JP; Kim MK
Cancer Rep (Hoboken); 2021 Oct; 4(5):e1387. PubMed ID: 33835729
[TBL] [Abstract][Full Text] [Related]
17. Endocrinological Toxicity Secondary to Treatment of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs).
Alexandraki KI; Daskalakis K; Tsoli M; Grossman AB; Kaltsas GA
Trends Endocrinol Metab; 2020 Mar; 31(3):239-255. PubMed ID: 31839442
[TBL] [Abstract][Full Text] [Related]
18. The Role of Chemotherapy in Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors.
Strosberg J; Goldman J; Costa F; Pavel M
Front Horm Res; 2015; 44():239-47. PubMed ID: 26303716
[TBL] [Abstract][Full Text] [Related]
19. Biotherapies for GEP-NETs.
Öberg K
Best Pract Res Clin Gastroenterol; 2012 Dec; 26(6):833-41. PubMed ID: 23582922
[TBL] [Abstract][Full Text] [Related]
20. Plasma chromogranin A levels predict survival and tumor response in patients with advanced gastroenteropancreatic neuroendocrine tumors.
Chou WC; Chen JS; Hung YS; Hsu JT; Chen TC; Sun CF; Lu CH; Hwang TL
Anticancer Res; 2014 Oct; 34(10):5661-9. PubMed ID: 25275071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
